Silvia Chang

567 total citations
22 papers, 363 citations indexed

About

Silvia Chang is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Silvia Chang has authored 22 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Infectious Diseases, 13 papers in Virology and 9 papers in Epidemiology. Recurrent topics in Silvia Chang's work include HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (13 papers) and HIV/AIDS Research and Interventions (9 papers). Silvia Chang is often cited by papers focused on HIV/AIDS drug development and treatment (14 papers), HIV Research and Treatment (13 papers) and HIV/AIDS Research and Interventions (9 papers). Silvia Chang collaborates with scholars based in United States, France and United Kingdom. Silvia Chang's co-authors include Ross Martin, Kirsten White, Hal Martin, Rima Acosta, Erin Quirk, Madeleine Willkom, Bandita Parhy, Hongmei Mo, Kristen Andreatta and Tarik Asselah and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Gastroenterology and Journal of Virology.

In The Last Decade

Silvia Chang

22 papers receiving 357 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Silvia Chang United States	11	237	175	148	131	44	22	363
Janine Roney Australia	7	134 0.6×	161 0.9×	127 0.9×	158 1.2×	17 0.4×	18	363
Roy M. Matining United States	8	208 0.9×	79 0.5×	49 0.3×	185 1.4×	76 1.7×	13	331
Federico Hinestrosa United States	10	160 0.7×	278 1.6×	295 2.0×	47 0.4×	36 0.8×	28	404
Reiner Babiel Switzerland	8	256 1.1×	145 0.8×	100 0.7×	212 1.6×	16 0.4×	10	394
Giuliana Cologni Italy	11	215 0.9×	141 0.8×	83 0.6×	168 1.3×	98 2.2×	20	358
Almudena Torres-Cornejo Spain	11	157 0.7×	176 1.0×	202 1.4×	108 0.8×	21 0.5×	28	337
Cyril Llamoso United States	13	246 1.0×	354 2.0×	326 2.2×	188 1.4×	20 0.5×	33	565
Alex Dusek United States	5	324 1.4×	66 0.4×	37 0.3×	302 2.3×	31 0.7×	7	399
Kawthar Machmach Spain	11	92 0.4×	86 0.5×	50 0.3×	236 1.8×	40 0.9×	20	346
Mette Sannes Norway	9	191 0.8×	192 1.1×	139 0.9×	208 1.6×	62 1.4×	13	429

Countries citing papers authored by Silvia Chang

Since Specialization

Citations

This map shows the geographic impact of Silvia Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Chang more than expected).

Fields of papers citing papers by Silvia Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Chang. The network helps show where Silvia Chang may publish in the future.

Co-authorship network of co-authors of Silvia Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Chang. A scholar is included among the top collaborators of Silvia Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Chang. Silvia Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Andreatta, Kristen, Michelle L. D’Antoni, Silvia Chang, et al.. (2024). High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence. Journal of Medical Virology. 96(10). e29899–e29899. 6 indexed citations

Aggarwal, Abhishek, Pamela M. Odorizzi, Jens Brodbeck, et al.. (2022). Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells. JHEP Reports. 5(4). 100664–100664. 17 indexed citations

Liu, Yang, Dmytro Kornyeyev, Lindsey May, et al.. (2022). Establishment and Characterization of an HBV Viral Spread and Infectious System following Long-Term Passage of an HBV Clinical Isolate in the Primary Human Hepatocyte and Fibroblast Coculture System. Journal of Virology. 96(18). e0084922–e0084922. 3 indexed citations

Chang, Silvia, Charlotte Hedskog, Bandita Parhy, et al.. (2022). Sequence characterization of extracellular HBV RNA in patient plasma. Journal of Viral Hepatitis. 30(1). 29–38. 1 indexed citations

Sax, Paul E., Kristen Andreatta, Jean‐Michel Molina, et al.. (2022). High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I. AIDS. 36(11). 1511–1520. 14 indexed citations

Liu, Yang, Silvia Chang, David Hsieh, et al.. (2021). Generation of an HBV core phenotyping assay for evaluating HBV capsid compounds. Journal of Virological Methods. 292. 114117–114117. 2 indexed citations

D’Antoni, Michelle L., Kristen Andreatta, Rima Acosta, et al.. (2021). Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials. JAIDS Journal of Acquired Immune Deficiency Syndromes. 89(4). 433–440. 7 indexed citations

VanderVeen, Laurie A., Nicolas Margot, Silvia Chang, et al.. (2021). 73. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks. Open Forum Infectious Diseases. 8(Supplement_1). S48–S48. 6 indexed citations

Lo, Michael K., César G. Albariño, Jason K. Perry, et al.. (2020). Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. Proceedings of the National Academy of Sciences. 117(43). 26946–26954. 45 indexed citations

10.

Mulato, Andrew, Rima Acosta, Silvia Chang, et al.. (2020). Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 86(3). 369–377. 10 indexed citations

11.

D’Antoni, Michelle L., Kristen Andreatta, Rima Acosta, et al.. (2020). 633. Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Efficacy in Participants with Pre-Existing Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials. Open Forum Infectious Diseases. 7(Supplement_1). S376–S377. 1 indexed citations

12.

Liu, Yang, Silvia Chang, Ross Martin, et al.. (2020). Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance. Journal of Viral Hepatitis. 28(1). 30–39. 11 indexed citations

13.

Andreatta, Kristen, Michelle L. D’Antoni, Silvia Chang, et al.. (2020). 109. Preexisting Resistance and Week 48 Virologic Outcomes After Switching to B/F/TAF in African American Adults with HIV. Open Forum Infectious Diseases. 7(Supplement_1). S183–S184. 1 indexed citations

14.

Andreatta, Kristen, Madeleine Willkom, Ross Martin, et al.. (2019). Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. Journal of Antimicrobial Chemotherapy. 74(12). 3555–3564. 49 indexed citations

15.

Acosta, Rima, Madeleine Willkom, Ross Martin, et al.. (2019). Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks. Antimicrobial Agents and Chemotherapy. 63(5). 41 indexed citations

16.

Hedskog, Charlotte, Bandita Parhy, Silvia Chang, et al.. (2019). Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification. Open Forum Infectious Diseases. 6(3). ofz076–ofz076. 79 indexed citations

17.

Wyles, David, Eric Lawitz, Brian McNabb, et al.. (2018). 720 - Emergence and Long-Term Persistence of NS3, NS5A, and NS5B Resistance Associated Substitutions after Treatment with Direct-Acting Antivirals. Gastroenterology. 154(6). S–1104. 1 indexed citations

18.

Cathcart, Andrea L., Henry Lik‐Yuen Chan, Neeru Bhardwaj, et al.. (2018). No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrobial Agents and Chemotherapy. 62(10). 39 indexed citations

19.

Kulkarni, Rima, Sally Hodder, Huyen Cao, et al.. (2017). Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128). HIV Clinical Trials. 18(4). 164–173. 3 indexed citations

20.

Porter, Danielle, Alexander Thielen, Silvia Chang, et al.. (2015). Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study. Viruses. 7(12). 6360–6370. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact